JPY 460.0
(-7.26%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 1.47 Billion JPY | 62.56% |
2022 | 906.81 Million JPY | -31.53% |
2021 | 1.32 Billion JPY | -38.72% |
2020 | 2.16 Billion JPY | -0.04% |
2019 | 2.16 Billion JPY | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 827 Million JPY | -13.18% |
2023 Q4 | 1.47 Billion JPY | -17.19% |
2023 Q3 | 1.78 Billion JPY | 262.72% |
2023 Q2 | 490.77 Million JPY | -37.67% |
2023 Q1 | 787.33 Million JPY | -13.18% |
2023 FY | 1.47 Billion JPY | 62.56% |
2022 Q3 | 952 Million JPY | 29.78% |
2022 Q2 | 733.57 Million JPY | 0.0% |
2022 Q4 | 906.81 Million JPY | -4.75% |
Name | Total Assets | Total Assets Difference |
---|---|---|
KOHJIN BIO CO LTD | 6.58 Billion JPY | 77.628% |
PRISM BioLab Co.,LTD | 1.21 Billion JPY | -21.688% |
GNI Group Ltd. | 62.39 Billion JPY | 97.637% |
Linical Co., Ltd. | 18.53 Billion JPY | 92.049% |
Trans Genic Inc. | 9.81 Billion JPY | 84.974% |
MEDINET Co., Ltd. | 5.63 Billion JPY | 73.835% |
Soiken Holdings Inc. | 6.94 Billion JPY | 78.777% |
Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 74.655% |
AnGes, Inc. | 28.89 Billion JPY | 94.898% |
OncoTherapy Science, Inc. | 867.27 Million JPY | -69.975% |
Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 99.062% |
Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | 8.923% |
NanoCarrier Co., Ltd. | 5.07 Billion JPY | 70.931% |
Carna Biosciences, Inc. | 4.34 Billion JPY | 66.111% |
CanBas Co., Ltd. | 2.43 Billion JPY | 39.406% |
D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 37.888% |
RaQualia Pharma Inc. | 6.93 Billion JPY | 78.729% |
Chiome Bioscience Inc. | 1.75 Billion JPY | 15.833% |
Kidswell Bio Corporation | 5.08 Billion JPY | 71.013% |
PeptiDream Inc. | 67.12 Billion JPY | 97.804% |
Oncolys BioPharma Inc. | 2.04 Billion JPY | 27.759% |
Ribomic Inc. | 3.54 Billion JPY | 58.442% |
SanBio Company Limited | 5.04 Billion JPY | 70.793% |
Healios K.K. | 15.15 Billion JPY | 90.273% |
BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -19.825% |
Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 51.122% |
StemRIM | 9.08 Billion JPY | 83.765% |
CellSource Co., Ltd. | 6.87 Billion JPY | 78.573% |
FunPep Company Limited | 2.49 Billion JPY | 40.824% |
Kringle Pharma, Inc. | 2.61 Billion JPY | 43.706% |
Stella Pharma Corporation | 3.82 Billion JPY | 61.416% |
TMS Co., Ltd. | 3.55 Billion JPY | 58.53% |
Noile-Immune Biotech Inc. | 5.77 Billion JPY | 74.491% |
Cuorips Inc. | 6.18 Billion JPY | 76.165% |
K Pharma,Inc. | 3.31 Billion JPY | 55.516% |
Takara Bio Inc. | 123.2 Billion JPY | 98.804% |
ReproCELL Incorporated | 9.05 Billion JPY | 83.716% |
PhoenixBio Co., Ltd. | 2.71 Billion JPY | 45.71% |
StemCell Institute Inc. | 6.54 Billion JPY | 77.47% |
Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 78.907% |
CellSeed Inc. | 2.46 Billion JPY | 40.215% |